Sanofi has been actively involved in a number of new developments and challenges in the biotech sector. Sanofi has returned the midstage ILT2 asset to Biond Biologics after a $125M investment and is leading early flu vaccine preparation efforts. An FDA action alert has been issued involving a number of companies including Sanofi. The company has adopted a strategy aligning itself with FDA-selected flu strains to be prepared for subsequent flu seasons. Sanofi is also under investigation by the South African watchdog over insulin alongside Novo Nordisk. The company has gained backing from Enveda to advance AI-Driven Drug Discovery to clinical trials, bringing its Total Series C Financing to a whopping $150M. Sanofi also announced the cancellation of its consumer healthcare business spin-off. The company's earnings were boosted by Dupixent and a new RSV vaccine while it continued its hunt for deals. Despite facing several challenges such as a lawsuit from Regeneron and a hefty $250M hit after a gamble on a J&J E.Coli vaccine ended in phase 3 failure, the company has remained proactive in pursuing innovative strategies in the biotech market.
Sanofi News Analytics from Wed, 22 May 2024 07:00:00 GMT to Fri, 14 Mar 2025 19:24:50 GMT - Rating 7 - Innovation 8 - Information 7 - Rumor -5
